Endless evolution of cancer immunotherapy

The approval for the expansion of indications continues

Opdivo, gastroesophageal junction cancer supplementary therapy, etc. are added

According to related industries, news of approval for the expansion of domestic indications of cancer immunotherapy Opdivo (Nivolumab) and Keytruda (Pembrolizumab) in PD-1 inhibition mechanisms continues.

 

Although it is the same mechanism, it is competing by securing different indications.

 

In the case of Opdivo, two postoperative adjuvant therapy and three combined therapy indications were added.

 

Postoperative adjuvant therapy in patients with esophageal cancer or gastroesophageal junction cancer with residual pathological diseases after receiving chemotherapy (CRT) as a preoperative adjuvant therapy and Postoperative adjuvant therapy in patients with root resection were added.

 

Combination therapy with Carboplatin, Paclitaxel, and Bevacizumab as the primary treatment for metastatic or recurrent non-small cell lung cancer patients without EGFR or ALK mutation and combination therapy with Cabozantinib as the primary treatment of advanced Neoplasmine, and Fluoropyrimidine, Oxaliplatin and combination therapy with Yervoy (Ipilimumab) was also added to the treatment of adult patients with metastatic direct bowel cancer with microsatellite instability-high (MSI-H) or dMMR that recurred after Irinotecan treatment.

 

As a result, Opdivo can be used alone or with other treatments such as melanoma, non-small cell lung cancer, malignant pleural mesothelioma, renal cell cancer, typical Hodgkin lymphoma, head and neck squamous cell cancer, urinary epithelial cell cancer, gastric cancer, gastroesophageal adenocarcinoma, esophageal cancer, and direct bowel cancer.

 

In the case of Keytruda, it entered the field of renal and endometrial cancer through Lenvima combination therapy.

 

The permission for the first-line treatment indication for renal cell cancer was based on data from the CLEAR study (KEYNOTE-581/Study 307), a phase 3 clinical trial.

 

In the CLEAR study, Keytruda-Lenvima combination therapy demonstrated statistically significant Progression-Free Survival (PFS) and Overall Survival (OS) improvements over the existing treatments Sunitinib.

 

Keytruda-Lenvima combination therapy reduced the risk of disease progression or death by 61% and the risk of death by 34% compared to Sunitinib.